This site is intended for Healthcare Professionals outside the US

MF
PV
  1. About MF
  2. Prognosis

Myelofibrosis is associated with severe, frequent symptom burden1

Progressive, relentless symptoms impair QoL and increase disability2-4

  • MF-related symptoms compromise social functioning, physical activity, independence, and QoL1,5
  • Constitutional MF symptoms negatively impact QoL and are associated with poor prognosis for survival4,6
  • Fatigue is extremely common and is similar to or worse than that suffered by patients undergoing chemotherapy for haematologic malignancies7

High incidence and wide variety of symptoms of MF1

Splenomegaly and other symptoms have high incidence in patients with Myelofibrosis - JAKAVI

Adapted from: Scherber R et al. Blood. 2011;118:401-408.1

QoL scores for MF patients were worse than those for all cancer patients combined8

Mean baseline EORTC QLQ-C30 HRQoL scores for patients with MF (COMFORT-II) compared with scores for all cancer patients by age group8

Prognosis for MF patients were worse than those for all cancer patients combined - JAKAVI

Adapted from: Kiladjian J et al. Poster presented at ASCO Annual Meeting, 2012.8

Learn more about QoL improvement with JAKAVI

MF-related symptoms are progressive and may worsen even with conventional therapies9,10

Symptom scores worsened with placebo9

Symptoms of Myelofibrosis are progressive and may worsen with conventional therapies - JAKAVI

Adapted from: Verstovsek S et al. N Engl J Med. 2012;366:799-807.9

Symptoms measured with the use of a modified Myelofibrosis Symptom Assessment Form (MFSAF), version 2.0.

Symptoms scores worsened from baseline with conventional therapies throughout 48-week study period10

Myelofibrosis-related symptoms including appetite loss, insomnia, dyspnea, pain, and fatigue worsened with conventional therapies during a 48-week study period - JAKAVI

Adapted from: Harrison C et al. N Engl J Med. 2012;366:787-798.10

Symptoms measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core model.

Learn more about significant symptom improvement with JAKAVI

Next: Rapid, significant, and durable spleen reduction with JAKAVI

COMFORT=Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment; EORTC QLQ-C30 RQoL=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; MF=myelofibrosis; QoL=quality of life.

References:

  1. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-408.
  2. Mesa RA, Kiladjian J-J, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014;99(2): 292-298.
  3. Verstovsek S, Almomen AK, Newberry KJ, Aleem A. Development of ruxolitinib as a myelofibrosis therapy. J Appl Hematol. 2013;4(3):89-95.
  4. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101.
  5. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103.
  6. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121(24):4832-4837.
  7. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76.
  8. Kiladjian J-J, Gisslinger H, Passamonti F, et al. Health-related quality of life and symptom burden in patients with myelofibrosis in the COMFORT-II study. Poster presented at: 48th Annual Meeting of American Society of Clinical Oncology; June 1-5, 2012; Chicago, IL.
  9. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
  10. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.